sEH Inhibition in Alcoholic Liver Disease: A Novel Therapeutic Strategy

酒精性肝病中的 sEH 抑制：一种新的治疗策略

• 批准号: 10254281
• 负责人: Jeffrey B Warner
• 金额: $ 3.28万
• 依托单位: UNIVERSITY OF LOUISVILLE
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-01 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10254281
• 关键词: ANXA5 gene; Ablation; Affect; Alcoholic Hepatitis; Alcoholic Liver Diseases; Alcohols; Animals; Anti-Inflammatory Agents; Area; Attenuated; Basic Science; Biological; Biological Assay; CXCL1 gene; Cell Death; Cell Line; Cell physiology; Cells; Cellular biology; Cessation of life; Chronic; Clinical; Clinical Research; Data; Development; Disease; Ensure; Environment; Enzyme-Linked Immunosorbent Assay; Epoxide hydrolase; Epoxy Compounds; Ethanol; FDA approved; Fatty Acids; Flow Cytometry; Fostering; Funding; Genetic; Goals; Health; HepG2; Hepatic; Hepatocyte; Histologic; Human; IL6 gene; Immune; Individual; Inflammation; Inflammatory; Interleukin-1 beta; Knock-out; Knockout Mice; Kupffer Cells; Laboratories; Learning; Lipids; Liver; Liver diseases; Medical; Mentors; Modeling; Mus; Neutrophil Infiltration; Oral; Organ; Palmitic Acids; Pathogenesis; Pathology; Patients; Pharmaceutical Preparations; Pharmacology; Pharmacology and Toxicology; Phenotype; Physiological; Polyunsaturated Fatty Acids; Positioning Attribute; Predisposition; Prevention; Production; Propidium Diiodide; Research; Research Personnel; Resolution; Resources; Role; Scientist; Slide; Stains; Supervision; TNF gene; Techniques; Testing; Therapeutic; Training; Translational Research; Translations; Travel; Universities; Work; alcohol exposure; bench to bedside; career; career development; career networking; chronic liver disease; cytokine; efficacy evaluation; experience; experimental study; faculty research; feeding; improved; in vivo; inhibitor/antagonist; lipid mediator; lipidome; lipidomics; liver inflammation; liver injury; macrophage; mouse model; novel therapeutic intervention; novel therapeutics; oral communication; pre-clinical; prevent; recruit; skills; success; treatment strategy

Project Summary Alcoholic liver disease (ALD) is the most common liver disease and is responsible for nearly half of all deaths from diseases affecting this organ. Despite this, there remain no FDA-approved treatments for any stage of the disease, highlighting the need for the discovery of new therapies. As an aspiring scientist whose goal is to pursue a career in alcohol-related multi-organ pathology, investigating new therapies for ALD treatment would not only help fill this medical need but also serve as an excellent platform from which to learn how to become a successful scientist. With the help and supervision of my co-mentors Dr. Kirpich (an expert in basic research on ALD) and Dr. McClain (an expert on clinical aspects of the disease) as well as several knowledgeable collaborators, I will investigate soluble epoxide hydrolase (sEH) inhibition as a novel therapeutic strategy for the treatment of ALD using pre-clinical mouse models. This approach has been applied to other inflammatory diseases, but not to ALD, a disease shown by previous work in our group to be characterized by a loss of anti-inflammatory epoxygenated lipids (epoxides), in part due to their rapid degradation by sEH. I have generated substantial preliminary data with an orally-administered sEH inhibitor in a chronic-binge mouse model of ALD that recapitulates human ALD. Through two related, but independent, specific aims proposed in this application I will further assess the efficacy of sEH inhibition and explore its mechanisms of action. Aim 1 will use pharmacological and genetic ablation of sEH to further characterize the effects of sEH inhibition in mouse models of ALD. Aim 2 will describe the mechanistic effects of individual anti-inflammatory epoxides on changes in hepatocyte and immune cell health and function to explain changes seen in vivo. To complete this research, I will follow a detailed training plan laid out for me by my co-mentors and pursue the career goals that I have set for myself. These include, among others, continuing my didactic training in areas relevant to my research, gaining experience in new laboratory techniques, developing effective written and oral communication skills, and building a professional network of scientists. For example, to assess liver injury and changes in cellular function I will learn to read histological liver slides, use enzymatic assays, set up ELISAs, isolate and culture primary hepatocytes and macrophages, and learn flow cytometry. The research environment at the University of Louisville’s state-of- the-art Clinical and Translational Research Building is highly productive and staffed with expert faculty and research personnel willing to help me learn these techniques and advise me as I pursue my training and career goals. My academic department, the Department of Pharmacology & Toxicology, is equally positioned to support my training in the classroom and provide many resources (e.g. travel funds, career development seminars, and new courses) to ensure my success. Collectively, the training and research proposed here will not only fill a significant need for the development of ALD treatments, but will also foster my development from a young scientist to a successful, independent investigator in the field of alcohol-induced organ disease.

项目摘要 酒精性肝病(ALD)是最常见的肝病，占所有死亡病例的近一半 远离影响这个器官的疾病。尽管如此，仍然没有FDA批准的任何阶段的治疗方法 疾病，突出了发现新疗法的必要性。作为一个有抱负的科学家，他的目标是 从事酒精相关的多器官病理学，研究ALD治疗的新疗法不仅会 帮助满足这种医疗需求，也是一个学习如何成为成功人士的极好平台 科学家。在我的共同导师Kirpich博士(ALD基础研究专家)的帮助和监督下， McClain博士(该病临床方面的专家)以及几位知识渊博的合作者，我将 探讨抑制可溶性环氧化物水解酶作为治疗酒精性肝病的新策略 使用临床前的小鼠模型。这种方法已经应用于其他炎症性疾病，但不适用于 ALD，我们小组以前的工作显示的一种疾病，其特征是失去抗炎作用 环氧脂(环氧化物)，部分原因是它们被sEH迅速降解。我已经产生了大量的 口服sEH抑制剂在慢性暴饮性酒精性肝病小鼠模型中的初步数据 概括了人类的ALD。通过本申请中提出的两个相关但独立的具体目标，我将 进一步评估抑制sEH的疗效，并探讨其作用机制。目标1将使用药理学 和遗传消融sEH，以进一步表征sEH抑制ALD小鼠模型的效果。目标2 将描述个别抗炎环氧化物对肝细胞和 免疫细胞的健康和功能来解释在活体中看到的变化。为了完成这项研究，我将遵循详细的 我的同事为我制定了培训计划，并追求我为自己设定的职业目标。这些 包括，继续我在与我的研究相关的领域的教学培训，获得经验 新的实验室技术，培养有效的书面和口头沟通技能，并建立 科学家的专业网络。例如，为了评估肝脏损伤和细胞功能的变化，我将学习 为了阅读组织学肝切片，使用酶分析，建立ELISA，分离和培养原代肝细胞 和巨噬细胞，并学习流式细胞术。路易斯维尔大学的研究环境 先进的临床和翻译研究大楼生产力很高，拥有专业的教职员工和 研究人员愿意帮助我学习这些技术，并在我从事培训和职业生涯时给我建议 目标。我的学术部门，药理学和毒理学系，也同样支持 我在课堂上的培训，并提供许多资源(例如，旅行资金、职业发展研讨会和 新课程)，以确保我的成功。总的来说，这里提出的培训和研究不仅将填补 开发ALD治疗的重大需要，也将促进我从年轻时的发展 科学家在酒精引起的器官疾病领域成为一名成功的、独立的研究者。